La cadena de opciones muestra datos clave de las opciones de acciones de Myomo a varios precios de ejercicio y fechas de vencimiento. Los operadores utilizan esta información para analizar posibles operaciones y evaluar el sentimiento del mercado para Myomo..

Myomo (AMEX:MYO) Bolsa, Cadena de Opciones

Myomo

Myomo Inc is a wearable medical robotics company that develops, designs, and produces myoelectric orthotics for people with neuromuscular disorders. The MyoPro myoelectric upper limb orthosis product is registered with the Food and Drug Administration as a Class II medical device. The Company provides the devices to patients and bills their insurance companies directly, sometimes utilizing the clinical services of orthotics and prosthetics providers for which a fee is paid. The Company sells the product to orthotics and prosthetics providers around the world and the Veterans Health Administration (VA).

Myomo Inc

News

Guidance

ABM Indus Raised The Lower End Of Its FY25 Adjusted EPS Outlook By $0.05, Now Expecting Adjusted EPS To Range From $3.65 To $3.80 Vs. Cons. Of $3.73

PWNX

Prestige Wealth's InnoSphere Tech Subsidiary Integrates DeepSeek

WIIM

OPRX

OptimizeRx shares are trading higher after the company reported better-than-expected Q4 earnings and sales.

TRNR

Interactive Strength shares are trading higher after the company secured $3.6 million in 3-year notes from an institutional investor, following a $2.9 million investment.

Stifel analyst Brian Brophy maintains Limbach Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LMB#NASDAQ">LMB</a>) with a Buy and raises the price target from $102 to $103.

Price Target

Analyst Ratings

Stifel Maintains Buy on Limbach Holdings, Raises Price Target to $103

Telsey Advisory Group analyst Dana Telsey maintains Kohl's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KSS#NYSE">KSS</a>) with a Market Perform and lowers the price target from $13 to $10.

Telsey Advisory Group Maintains Market Perform on Kohl's, Lowers Price Target to $10

Stifel analyst Jim Duffy maintains Dick's Sporting Goods (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DKS#NYSE">DKS</a>) with a Hold and lowers the price target from $240 to $226.

Stifel Maintains Hold on Dick's Sporting Goods, Lowers Price Target to $226

HC Wainwright &amp; Co. analyst Yi Chen maintains LifeMD (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LFMD#NASDAQ">LFMD</a>) with a Buy and raises the price target from $12 to $14.

LFMD

HC Wainwright & Co. Maintains Buy on LifeMD, Raises Price Target to $14

ONDS

Ondas Sees FY25 Revenue Of $25M Vs. $33.44M Est.

Ondas Posts Q4 Net Loss Of $10.3M Versus $14.1M In Q4 FY23

HC Wainwright &amp; Co. analyst Yi Chen maintains Zynex (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZYXI#NASDAQ">ZYXI</a>) with a Buy and lowers the price target from $17 to $15.

ZYXI

HC Wainwright & Co. Maintains Buy on Zynex, Lowers Price Target to $15

Ondas Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ONDS#NASDAQ">ONDS</a>) reported quarterly sales of $7.19 million which beat the analyst consensus estimate of $5.75 million by 25.08 percent. This is a 44.97 percent increase over sales of $4.96 million the same period last year.

Earnings

Earnings Beats

Ondas Holdings Q4 Sales $7.19M Beat $5.75M Estimate

HC Wainwright &amp; Co. analyst Raghuram Selvaraju reiterates BrainsWay (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BWAY#NASDAQ">BWAY</a>) with a Buy and maintains $16 price target.

Reiteration

BWAY

HC Wainwright & Co. Reiterates Buy on BrainsWay, Maintains $16 Price Target

Telsey Advisory Group analyst Dana Telsey maintains Grove Collaborative Hldgs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GROV#NYSE">GROV</a>) with a Outperform and maintains $2 price target.

GROV

Telsey Advisory Group Maintains Outperform on Grove Collaborative Hldgs, Maintains $2 Price Target

Sprinklr Sees FY26 Revenues Between $821.5M-$823.5M Vs. $819.73M Estimate, With Adjusted EPS Of $0.38-$0.39 Vs. $0.38 Estimate

Needham analyst Serge Belanger reiterates Verrica Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRCA#NASDAQ">VRCA</a>) from Hold to Hold.

VRCA

Needham Reiterates Hold on Verrica Pharmaceuticalsto Hold

Sprinklr Sees Q1 Revenues Between $201.5M-$202.5M Vs. $200.41M Estimate, With Adjusted EPS Of $0.10 Vs. $0.08 Estimate

The chairperson of Alibaba Group Holding ADR (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BABA#NYSE">BABA</a>), Joseph Tsai acknowledged that everyone around the world is concerned about the ongoing tariff battle between the economic powerhouses of the world.
What Happened: While speaking at CNBC&#8217;s event Converge Live, in Singapore, Tsai responded to a question on tariff imposition by the Donald Trump administration and said that &#8220;Everyone is concerned about tariffs.&#8221;
He highlighted that the Chinese multinational technology company sells $50 billion worth of American products on its platform to Chinese consumers every year. On the other hand, about $30 billion worth of European products are also sold annually.
"I think the Trump administration will want to have more American companies doing business in China and making money there," he said, adding that it was ultimately between the global leaders to meet and decide on the future course of these protectionist policies.
Furthermore, he suggested if Trump&#8217;s wider tariff approach was just a bargaining chip, there was still a likelihood of seeing specific tariffs on Chinese electric vehicles. Tsai added that it could be a move to safeguard the American auto industry from potential competition.
See Also: <a href="https://www.benzinga.com/25/03/44269729/debt-over-equity-billionaire-howard-marks-endorses-credit-investments-amid-shifting-investor-focus-and-market-correction">Billionaire Howard Marks Prefers Credit Over Equity Amid Falling Market: &#8216;Yields Implies Higher Returns From Credit Than The S&amp;P 500&#8217;</a>
Why It Matters: On Tuesday afternoon, President Trump unexpectedly reversed his decision to double tariffs on Canadian steel and aluminum to 50%, just hours after announcing the increase. The abrupt policy change, which rattled financial markets, followed Canada&#8217;s withdrawal of plans for a 25% surcharge on electricity.
Additionally, as Trump&#8217;s tariffs on steel and aluminum imports go into effect, the European Union announced on Wednesday that it will retaliate by imposing levies of 26 billion euros or $28.33 billion on U.S. goods beginning in April.
Price Action: The SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>) and Invesco QQQ Trust ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>), which track the S&amp;P 500 index and Nasdaq 100 index, respectively, rose in premarket on Wednesday. The SPY was up 0.73% to $560.00, and the QQQ also advanced 0.83% to $475.51, according to <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a> data.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/market-summary/25/03/44245897/billionaire-investor-ron-baron-reacts-to-nasdaq-sp-selloff-the-stock-prices-cant-believe-how-cheap-they-are" target="_blank" rel="noreferrer noopener">Billionaire Investor Ron Baron Reacts To Nasdaq, S&amp;P Selloff: ‘The Stock Prices…Can't Believe How Cheap They Are'</a></li>
</ul>
Photo courtesy: Shutterstock

Equities

Government

Global

Economics

Markets

BABA

Alibaba's Joseph Tsai Says 'Everyone Is Concerned About Tariffs,' As He Expects Levies On Chinese EVs

HC Wainwright &amp; Co. analyst Andres Maldonado reiterates Corbus Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRBP#NASDAQ">CRBP</a>) with a Buy and lowers the price target from $75 to $50.

CRBP

HC Wainwright & Co. Reiterates Buy on Corbus Pharmaceuticals, Lowers Price Target to $50

United Homes Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UHG#NASDAQ">UHG</a>) reported quarterly earnings of $0.01 per share. This is a 100.72 percent increase over losses of $(1.38) per share from the same period last year. The company reported $134.81 million in sales this quarter. This is a 15.39 percent increase over sales of $116.83 million the same period last year.

United Homes Gr Q4 EPS $0.01 Up From $(1.38) YoY, Sales $134.81M Up From $116.83M YoY

Press Releases

Myomo, Inc. Announces the Launch of Myomo Academy at AOPA National Assembly

Myomo to Participate in the 2024 Maxim Healthcare Virtual Summit

Myomo to Report Third Quarter Financial Results on November 6, 2024

Myomo Announces First Private Payer Contracts for MyoPro In-network Coverage

Myomo Reports Record Third Quarter Financial and Operating Results

Myomo, Inc. Announces Proposed Public Offering of Common Stock

Myomo, Inc. Prices $15.0 Million Public Offering of Common Stock

Inogen Announces Appointment of Mira Kirti Sahney to Board of Directors and Retirement of Board Member Tom West

Myomo to Report Fourth Quarter 2024 Financial Results on March 10

Myomo's Fourth Quarter Financial Results Feature Record Revenue of $12.1 Million

Comments

Myomo

Myomo (MYO) Opciones

Myomo (AMEX:MYO) Bolsa, Cadena de Opciones

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL